Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 68, Issue 2, 2009, Pages 175-182

  Visvanathan, S ^a   Van Der Heijde, D ^b   Deodhar, A ^c   Wagner, C ^a   Baker, D G ^a   Han, J ^a   Braun, J ^d  

^a CENTOCOR INC   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Rheumazentrum Ruhrgebiet ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; COLLAGEN TYPE 1; INFLIXIMAB; INTERLEUKIN 6; OSTEOCALCIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ABSORPTIOMETRY; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DRUG DOSE ESCALATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; X RAY ANALYSIS;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CERVICAL VERTEBRAE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOCALCIN; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 58849156499     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.084426     Document Type: Article

References (24)

1. Marhoffer W, Stracke H, Masoud I, Scheja M, Graef V, Bolten W, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995;54:556-9.
2. Yilmaz N, Ozaslan J, Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 2000;19:92-8.
3. Franck H, Keck E, Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 1993;52:343-6.
4. Speden DJ, Calin Al, Ring FJ, Bhalla AK. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis J Rheumatol 2002;29:516-21.
5. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, et al Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6
6. MacDonald AG, Birkinshaw G, Durham B, Bucknall RC,Fraser WD Biochemical markers of bone turnover in seronegative spondylarthropathy relationship to disease activity. Br J Rheumatol 1997;36:50-3
7. Toussirot E, Ricard-Blum S, Dumoulm G, Cedoz JP, Wendling D Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 1999;38:21-7
8. Acebes C, de la Piedra C, Traba ML, Seibel MJ, Garcia Martin C, Armas J, et al Biochemical markers of bone remodeling and bone sialoprotem in ankylosing spondylitis. Clin Chim Acta 1999;289:99-110.
9. Golmia RP, Sousa BD, Scheinberg MA. Increased osteoprotegerm and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article ov Gratacos et al. Arthritis Rheum 2002;46:3390-1, author reply 3392
10. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41
11. van der Heijde O, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P. et al Efficacy and safety of infliximab in patients with ankylosing spondylitis results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91
12. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis through 2 years Arthritis Rheum 2008;59:1270-8.
13. van der Heijde D, Landewe R, Baraliakos X, Hoouben H, van Tubergen A, Williamson P, et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis Arthritis Rheum 2008;58:3063-70.
14. Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622-32
15. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riei PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
16. Visvanathan S, Wagner CL, Marini JC, van der Heijde D, Baker D. Gathany T, et al Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis Published Online First: 20 July 2007. doi:10.1136/ard.2007.071605.
17. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003;62:347-9.
18. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ. et al Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1495-9.
19. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody a prospective open-label pilot study. Rheumatology 2005;44:1546-8
20. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease Am J Gastroenterol 2005;100:2031-5.
21. Bronson WD, Walker SE. Hillman LS, Keisler D, Hoyt T. Allen SH Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis J Rheumatol 1998;25:929-35.
22. Mitra D, Elvins DM, Collins AJ, Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J Rheumatol 1999;26:2201- 4.
23. Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006;40:55-63
24. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T. et al The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis Rheumatology 2006;45:761-4.